早期鼻咽癌缩小临床靶区与降低剂量的前瞻性10年观察研究
该前瞻性观察研究纳入103例WHO II-III型、AJCC/UICC第六版T1-2N0-1期鼻咽癌患者,单纯IMRT治疗,将CTVp分为高危CTVp1(60Gy/30fr)和低危CTVp2(54Gy/30fr)。中位随访15.2年,10年局部无复发生存90.3%、总生存91.2%,仅1例局部失败,晚期毒性轻微。结论提示早期鼻咽癌缩小CTV边界和降低剂量可获得长期肿瘤控制。
要点
- 早期鼻咽癌缩小CTVp边界并降低剂量至54-60Gy/30fr,10年局部控制良好。
- 中位随访15.2年仅1例局部失败,10年总生存91.2%。
- 晚期毒性轻微,无颞叶坏死、脑干损伤或张口困难。
核心结论
- 早期鼻咽癌缩小CTV边界和降低放疗剂量可获得长期肿瘤控制且晚期毒性轻微。
研究设计与样本
- 前瞻性观察研究,纳入103例新诊断、活检证实的WHO II-III型、AJCC/UICC第六版T1-2N0-1期鼻咽癌患者,单纯IMRT治疗,中位随访15.2年(范围2.1-18.1年)。
主要发现
- 10年局部无复发生存率90.3%、区域无复发生存率88.3%、无远处转移生存率90.3%、总生存率91.2%。
- 仅1例患者出现局部失败。
- 晚期不良事件包括2例G1颅神经损伤、3例G3听力丧失、3例G3皮下纤维化,无颞叶坏死、脑干损伤或张口困难。
关键数值与推荐
- CTVp1由大体肿瘤(MRI或增强CT)加5mm margin(后方3mm)构成,处方剂量60Gy/30fr。
- CTVp2由CTVp1加5mm margin(后方3mm)并排除上颌窦和海绵窦构成,处方剂量54Gy/30fr。
- 原发和颈部大体肿瘤体积(GTVp和GTVn)处方剂量分别为68Gy/30fr和60-66Gy/30fr。
临床怎么用
- 对早期鼻咽癌(T1-2N0-1)可考虑缩小CTVp边界并降低预防照射剂量至54-60Gy/30fr,以在保持肿瘤控制的同时减少晚期毒性。
局限性
- 本研究为单臂前瞻性观察研究,非随机对照,样本量103例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Current guideline recommends a uniform method of delineation of subclinical disease within the primary clinical target volume (CTVp) for all stages of nasopharyngeal carcinoma (NPC). We performed a prospective observational study to investigate the outcomes with a reduced CTVp and radiation dose for early-stage NPC. METHODS AND MATERIALS: Patients with newly diagnosed, biopsy-proven World Health Organization type II-III and American Joint Committee on Cancer/Union for International Cancer Control sixth edition stage T1-2N0-1 disease were enrolled. All patients were treated with intensity modulated radiation therapy alone. We categorized CTVp into CTVp1 (high risk) and CTVp2 (low risk). CTVp1 comprised of gross tumor (on magnetic resonance imaging or contrast-enhanced computed tomography) plus a 5-mm margin (3-mm posteriorly) and was prescribed to 60 Gy in 30 fractions (fr). CTVp2 was generated from CTVp1 plus a 5-mm margin (3 mm posteriorly), excluding the maxillary and cavernous sinuses, and was prescribed to 54 Gy in 30 fr. The prescribed doses to the primary and nodal gross tumor volume (GTVp and GTVn) were 68 Gy in 30 fr and 60 to 66 Gy in 30 fr, respectively. Primary endpoint was local recurrence-free survival. This study was registered in ClinicalTrials.gov, number NCT03839602. RESULTS: From May 2001 to August 2006, 103 patients were recruited and completed IMRT. With a median follow-up of 15.2 years (range, 2.1-18.1 years), only 1 patient had local failure. Ten-year local recurrence-free survival, regional recurrence-free survival, distant metastasis-free survival, and overall survival were 90.3%, 88.3%, 90.3%, and 91.2%, respectively. Among late IMRT-related adverse events, we recorded 2 patients with G1 cranial nerve injury, 3 patients with G3 hearing loss, and 3 patients with G3 subcutaneous fibrosis. No patients had temporal lobe necrosis, brain stem injury, or trismus. CONCLUSIONS: Decreased CTV margins and radiation doses can achieve long-term tumor control with mild late toxicities for patients with early-stage NPC.
引用
- Miao J, Di M, Chen B, et al. A Prospective 10-Year Observational Study of Reduction of Radiation Therapy Clinical Target Volume and Dose in Early-Stage Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2020. PMID: 32272183. doi:10.1016/j.ijrobp.2020.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。